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Editorial on the Research Topic
Modulation of Human Immune Parameters by Anticancer Therapies
Immunoncology is among the most important hallmarks of immunotherapy revolution of cancer
medicine. Here, we compiled reviews and original research articles reflecting current developments
in immunoncology.
Novel therapies modulate the complex interaction between tumor and immune system (Figure 1).
Multiparametric flow cytometry (FCM) is a key analytical tool contributing over 1,000 research articles/
year to the field. As a quantitative single-cell technology, FCM reliably and reproducibly identifies rare
populations, detects subtle changes in modulatory signals, and assesses time-sensitive antigenic
expression patterns. State-of-the-art equipment, fast sophisticated software, and flexibly labeled
monoclonal antibodies allow rapid analyses with high sensitivity and specificity, even in routine
applications. Lambert et al. explain how new analytes are added to the portfolio of diagnostic and
research laboratories. Sample preparation, antibody titration, and appropriate controls are central in
cytometric analysis and must be controlled with the necessary rigor and reproducibility (1).
Although tumor cell analysis is a key application of cytometry (2, 3), this research topic is
dedicated to the modulation of immune parameters, and we only included work focusing on tumor-
immune-cell interaction and its disease-course impact.
Dendritic cells (DCs) are crucial in tumor protection (4). Lu et al. dissect the interaction of DCs
with non-small cell lung cancer (NSCLC) cells, which can induce an immunosuppressive
microenvironment and evade immune surveillance. Analysis of costimulatory molecules and
pro-/anti-inflammatory cytokines reveals new subpopulations of CD1c+ DCs in coculture with
NSCLC. Particularly, the expression of signal molecules and pro-inflammatory cytokines are
suppressed, whereas the secretion of anti-inflammatory cytokines by DCs is upregulated,
suggesting that NSCLC can induce tolerogenic DCs, blocking DC-mediated anti-tumor immunity.
Chemokines and their corresponding receptors play a pivotal role in orchestrating trafficking of
immune cells to fulfill their next tasks. CXCL10 has been associated with T cell recruitment intoorg December 2020 | Volume 11 | Article 6215561
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cell infiltration with autophagy inhibition in gastric cancer (GC).
Since autophagy was associated with GC cell survival and
therapy resistance, autophagy inhibition is considered a
potential GC treatment strategy, which might also favorably
effect T cell recruitment into the tumor.
Inflammation is central in tumorigenesis underlining close
interactions between immune system and tumor. Besides adaptive
immunity, innate immunity is crucial in tumor defense (5). Stein
et al. address the role of the inflammatory cytokine TNF-a in
colorectal cancer (CRC). CRC has commonly good prognosis, if
detected early. With distant metastasis, 5-year survival rate drops
below 10% with little therapeutic progress. The metastasis-
associated oncogene in CRC 1 (MACC1) is involved in CRC
metastasis, induces cell proliferation and motility, supports cell
survival, and redirects metabolism. Also, in several other solid
cancers, MACC1 is a potential target for late forms of metastasis.
The authors demonstrate that TNF-a triggers upregulation of
MACC1 mRNA and protein via induction of c-Jun expression,
resulting in promoted CRC-cell migration. MACC1 induction was
successfully inhibited by MACC1 and c-Jun knockdown as well as
anti–TNF-a and anti-TNFR1 blocking antibodies, providing
potential therapeutic targets for treating inflammation-
associated CRC.
Tumor-immune-cell interactions are decisive in the disease
course but not yet fully understood and addressed by Plesca et al.
In various cancers, high densities of CD45RO+ T-helper1 cells
and CD8+ T cells are associated with improved outcome, M2
macrophages rather with worsened prognosis (5). This can also
be applied to the expected response to anti-programmed cell-
death-protein 1 (PD-1). Anti–PD-1 therapy affects an increased
density of tumor-infiltrating T cells in responders, and
increased frequency of melanoma-infiltrating TCF7+CD8+ TFrontiers in Immunology | www.frontiersin.org 2cells. However, tumor-infiltrating PD-1+CD38hi CD8+
T-cells are associated with anti–PD-1 resistance that
favors implementation of immunoprofiling before checkpoint
inhibition therapy.
Based on the manifold relationships between immune system
and tumor, the numerous parallels between immunopathology
and tumor therapy are not surprising. Khoy et al. present
Natalizumab in multiple sclerosis (MS) as a typical example for
immune therapies and precursor of today’s antibody therapies for
tumors. MS is a chronic demyelinating disease of the CNS with an
autoimmune component. Among the recently available disease-
modifying therapies, Natalizumab, a monoclonal antibody against
VLA-4 integrin, effectively inhibits cell migration to tissues
including the CNS, thereby inhibiting disease progression. Since
also immune function is impaired, immunomonitoring during
therapy is important to detect adverse effects.
Klöß et al. report on challenging examples that bridge between
treatment of cancer and immune-mediated diseases, major hurdles
are suitable experimental models reflecting the complex tumor-
immune-interactions during treatment for identifying new
therapies. In addition to patient-derived tumor xenotransplants
(PDX) (humanized) mouse models, ex vivo approaches to cancer
modeling like microfluidic human organs-on-chips are shown.
Better understanding of treatment mechanisms and side effects
permitted the development of novel targeted cell-, drug-, and
biological-based therapies. Progress of our knowledge about
inhibitory and stimulatory immune mechanisms associated with
autoimmune diseases enable novel strategies to tackle
autoimmunity using regulatory CAR-T cells (CAR Treg) of
natural killer cells (NK) (6, 7).
Cell-based therapies, particularly CAR-T or CAR-NK cells
redirected against aggressive leukemia and lymphoma, have
taught lessons to improve immunoncology. Identification ofFIGURE 1 | Tumor-immune-interactions and investigation by flow cytometry.December 2020 | Volume 11 | Article 621556
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interaction and understanding how to overcome the
immunosuppressive tumor-microenvironment are #1 challenges
as addressed in previous Frontiers in Immunology (8, 9). Current
development in CAR-NK cells for leukemia treatment (10–12) must
be applied also to solid tumors.
Gibellini et al. review single cell approaches to profile the
response to immune checkpoint inhibitors. Since tumor cells are
highly variable, single-cell analysis like polychromatic FCM, single-
cell sequencing, or high-resolution imaging can be employed to
examine rare tumor cells. These methods allow analyses in
unprecedented detail, fostering understanding of molecular and
cellular interactions between cancer and the immune system.
Unfortunately, analysis of tumor cells and immune signatures is
not per-se successful. For many cancer types, finding cancer stem
cells (CSCs) is essential for therapy optimization as Walcher et al.
highlight. They review the most used CSC markers focusing on
lung, gastric, liver, breast, and colon cancer andmyeloid leukemias.
CSCs are an integer part of tumors, drive tumor initiation and can
cause relapses. To date, several biomarkers characterizing CSCs
have been identified and correlated with diagnosis, therapy, and
prognosis. However, CSCs have a high plasticity altering their
phenotypic and functional appearance. Such changes are induced
by chemo- and radiotherapy as well as by senescent tumor cells,Frontiers in Immunology | www.frontiersin.org 3modifying the tumor microenvironment. One source of CSCs is
circulating tumor cells that are not part of this issue but are
addressed in recent overviews (13, 14).
The last article reports on drug actions immunomonitored by
high-content FCM (15, 16). Parry et al. investigated long-term
Ibrutinib therapy in B-Cell Chronic Lymphocytic Leukemia
(CLL). CLL is associated with immunosuppression and
susceptibility to infection. Investigating virus-specific CD8+
T cells, authors could demonstrate a reduction in PD-1
expression and increased cytokine production following
stimulation. The results suggest that Ibrutinib therapy is
associated with recovery of pathogen-specific T cells in B-CLL
thus contributing to reduced risk of infection.
In summary, we hope that this research topic adds important
facets to the picture of immunoncology.AUTHOR CONTRIBUTIONS
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